A study comparing 18f-Florbetaben quantification results using MR based and MR less CapAIBL and validation against histopathology.

Trial Profile

A study comparing 18f-Florbetaben quantification results using MR based and MR less CapAIBL and validation against histopathology.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Aug 2017

At a glance

  • Drugs Florbetaben F18 (Primary)
  • Indications Alzheimer's disease; Amyloidosis
  • Focus Diagnostic use
  • Most Recent Events

    • 23 Aug 2017 New trial record
    • 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top